Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma

Leukemia Research

Volumn 28, Issue 2, 2004, Pages 179-190

  Wun, Ted ^a,b   McKnight, Hayes ^a   Tuscano, Joseph M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Cyclooxygenase 2; Lymphoma; Pro apoptotic effect

Indexed keywords

CELECOXIB; CHLORAMBUCIL; CYCLOOXYGENASE 2; PHOSPHOTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; THYMIDINE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOMA; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 0344152223     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00183-8     Document Type: Article

References (70)

1. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J. Natl. Cancer Inst. 90:1998;1529-1536.
2. Hla T., Bishop-Bailey D., Liu C.H., Schaefers H.J., Trifan O.C. Cyclooxygenase-1 and cyclooxygenase-2 isoenzymes. Int. J. Biochem. Cell Biol. 31:1999;551-557.
3. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev. Clin. Lab Sci. 37:2000;431-502.
4. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
5. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. U.S.A. 93:1996;4816-4820.
6. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., Dubois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
7. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 55:1995;2556-2559.
8. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
9. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst. 90:1998;455-460.
10. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198-204.
11. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
12. Taketo M.M. COX-2 and colon cancer. Inflamm. Res. 47(Suppl 2):1998;S112-S116.
13. Tsujii M., Dubois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:1995;493-501.
14. Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res. 88:1997;600-604.
15. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., Dubois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
16. Erickson B.A., Longo W.E., Panesar N., Mazuski J.E., Kaminski D.L. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J. Surg. Res. 81:1999;101-107.
17. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. 274:1998;G1061-G1067.
18. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58:1998;4245-4249.
19. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;681-686.
20. Lipsky P.E. The clinical potential of cyclooxygenase-2-specific inhibitors. Am. J. Med. 106:1999;51S-57S.
21. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403.
22. Armitage J.O., Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J. Clin. Oncol. 16:1998;2780-2795.
23. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J. Lymphoma classification - from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann. Oncol. 11(Suppl 1):2000;3-10.
24. Chaganti R.S., Nanjangud G., Schmidt H., Teruya-Feldstein J. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin. Hematol. 37:2000;396-411.
25. Sarris A., Ford R. Recent advances in the molecular pathogenesis of lymphomas. Curr. Opin. Oncol. 11:1999;351-363.
26. 2-terminal kinase subgroup of mitogen-activated protein kinases in mesangial cells. Am. J. Physiol. 270:1996;F634-F641.
27. Sebahoun G., Maraninchi D., Carcassonne Y. Increased prostaglandin E production in malignant lymphomas. Acta Haematol. 74:1985;132-136.
28. Phipps R.P., Pollock S.J., Kaur K., Kaufman J., Borrello M.A., Graf B.A., et al. Expression of cyclooxygenase-2 and prostaglandins by B-1 cells and B-CLL cells. Curr. Top. Microbiol. Immunol. 252:2000;293-300.
29. Potter M., Wax J.S., Anderson A.O., Nordan R.P. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J. Exp. Med. 161:1985;996-1012.
30. Potter M., Wax J., Jones G.M. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Blood. 90:1997;260-269.
31. Tuscano J.M., Riva A., Toscano S.N., Tedder T.F., Kehrl J.H. CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood. 94:1999;1382-1392.
32. Parfenova H., Balabanova L., Leffler C.W. Post-translational regulation of cyclooxygenase by tyrosine phosphorylation in cerebral endothelial cells. Am. J. Physiol. 274:1998;C72-C81.
33. Lin M.T., Lee R.C., Yang P.C., Ho F.M., Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 276(52):2001;48997-49002.
34. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127:2001;411-417.
35. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu. Rev. Immunol. 13:1995;513-543.
36. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature. 369:1994;156-160.
37. Chen Y.R., Meyer C.F., Tan T.H. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in γ radiation-induced apoptosis. J. Biol. Chem. 271:1996;631-634.
38. Shi, C-S, Kehrl, JH. Activation of SAPK/JNK but not NF-κB, by the TNF receptor 1 through a TRAF-2 and CGKR-dependent pathway, 2001.
39. Berberich I., Shu G., Siebelt F., Woodgett J.R., Kyriakis J.M., Clark E.A. Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. EMBO J. 15:1996;92-101.
40. Guan Z., Buckman S.Y., Pentland A.P., Templeton D.J., Morrison A.R. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 273:1998;12901-12908.
41. Guan Z., Baier L.D., Morrison A.R. p38 Mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1β J. Biol. Chem. 272:1997;8083-8089.
42. Phipps R.P., Stein S.H., Roper R.L. A new view of prostaglandin E regulation of the immune response. Immunol. Today. 12:1991;349-352.
43. Roper R.L., Brown D.M., Phipps R.P. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J. Immunol. 154:1995;162-170.
44. Roper R.L., Phipps R.P. Prostaglandin E2 and cAMP inhibit B lymphocyte activation and simultaneously promote IgE and IgG1 synthesis. J. Immunol. 149:1992;2984-2991.
45. Stein S.H., Phipps R.P. Anti-class II antibodies potentiate IgG2a production by lipopolysaccharide-stimulated B lymphocytes treated with prostaglandin E2 and IFN-γ J. Immunol. 148:1992;3943-3949.
46. Plastaras J.P., Guengerich F.P., Nebert D.W., Marnett L.J. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J. Biol. Chem. 275:2000;11784-11790.
47. Weitzman S.A., Gordon L.I. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 76:1990;655-663.
48. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., Dubois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
49. Williams C.S., Tsujii M., Reese J., Dey S.K., Dubois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594.
50. Subbaramaiah K., Telang N., Bansal M.B., Weksler B.B., Dannenberg A.J. Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells. Ann. N.Y. Acad. Sci. 833:1997;179-185.
51. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7:2001;429-434.
52. Howe L.R., Subbaramaiah K., Chung W.J., Dannenberg A.J., Brown A.M. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 59:1999;1572-1577.
53. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., DeVito B., Weksler B.B., et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
54. Herschman H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta. 1299:1996;125-140.
55. Herschman H.R., Reddy S.T., Xie W. Function and regulation of prostaglandin synthase-2. Adv. Exp. Med. Biol. 407:1997;61-66.
56. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann. Clin. Lab Sci. 30:2000;3-21.
57. Cheson B.D. New drug development in non-Hodgkin lymphomas. Curr. Oncol. Rep. 3:2001;250-259.
58. Reed C.J. Apoptosis and cancer: strategies for integrating programmed cell death. Semin. Hematol. 37:2000;9-16.
59. Voutsadakis I.A. Apoptosis and the pathogenesis of lymphoma. Acta Oncol. 39:2000;151-156.
60. Richter M., Weiss M., Weinberger I., Furstenberger G., Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis. 22:2001;17-25.
61. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164:2000;820-825.
62. Soini Y., Raunio H., Paakko P. High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53. Tumor Biol. 19:1998;176-185.
63. Schlaifer D., Krajewski S., Galoin S., Rigal-Huguet F., Laurent G., Massip P., et al. Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection. Am. J. Pathol. 149:1996;177-185.
64. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:2000;1946-1952.
65. Alshafie G.A., Abou-Issa H.M., Seibert K., Harris R.E. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep. 7:2000;1377-1381.
66. Harris R.E., Alshafie G.A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103.
67. Moore R.J., Zweifel B.S., Heuvelman D.M. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Association Cancer Res. 41:2000;409. Ref Type: Abstract.
68. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 91:1999;1501-1504.
69. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L., et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331.
70. Blumenthal R.D., Waskewich C., Goldenberg D.M., Lew W., Flefleh C., Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin. Cancer Res. 7:2001;3178-3185.